[1. SEER Cancer Statistics Review (CSR), 1975-2011. Available at: seer.cancer.gov/csr/1975_2011/]Search in Google Scholar
[2. Scarfò L, Ferreri AJM, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169-182.10.1016/j.critrevonc.2016.06.003]Open DOISearch in Google Scholar
[3. Hallek M, Pflug N. Chronic lymphocytic leukemia. Annals of Oncology. 2010;21:vii154–vii164.10.1093/annonc/mdq373]Search in Google Scholar
[4. Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446-460.10.1002/ajh.23979]Search in Google Scholar
[5. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946-965.10.1002/ajh.24826]Search in Google Scholar
[6. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood. 2008;111:5446-5456.10.1182/blood-2007-06-093906]Search in Google Scholar
[7. Scarfò L, Ferreri AJM, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169-182.10.1016/j.critrevonc.2016.06.003]Open DOISearch in Google Scholar
[8. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.10.1182/blood.V87.12.4990.bloodjournal87124990]Search in Google Scholar
[9. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.10.1182/blood.V46.2.219.219]Search in Google Scholar
[10. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206.10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V]Search in Google Scholar
[11. Riwa S, Marcel M. Chronic Lymphocytic Leukemia (CLL): Upfront Treatment Options in 2017. Hematol Transfus Int J. 2017;4:00076.]Search in Google Scholar
[12. Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. 2014;99:965-972.10.3324/haematol.2013.096107]Search in Google Scholar
[13. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.10.1200/JCO.2005.12.051]Open DOISearch in Google Scholar
[14. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164-1174.10.1016/S0140-6736(10)61381-5]Search in Google Scholar
[15. Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine: cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975-980.10.1182/blood-2008-02-140582]Search in Google Scholar
[16. Strati P, Keating MJ, O’Brien SM, Burger J, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123:3727-3732.10.1182/blood-2013-11-538116]Search in Google Scholar
[17. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209-3216.10.1200/JCO.2011.39.2688]Open DOISearch in Google Scholar
[18. Eichhorst B, Fink AM, Busch R, et al. Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 Trial, an international, randomized study of the german CLL Study Group (GCLLSG). Blood. 2013;122:Suppl.21:abstract 526.10.1182/blood.V122.21.526.526]Search in Google Scholar
[19. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101-1110.10.1056/NEJMoa1313984]Search in Google Scholar
[20. Hillmen P, Robak T, Janssens A, et al. Ofatumumab + Chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). Blood. 2013;122:Suppl21:abstract 528.10.1182/blood.V122.21.528.528]Search in Google Scholar
[21. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:498-503.10.1200/JCO.2008.17.2619]Open DOISearch in Google Scholar
[22. O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase1b/2 trial. Lancet Oncol. 2014;15:48-58.10.1016/S1470-2045(13)70513-8]Search in Google Scholar
[23. Byrd JC, O’Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:1278-1279.10.1056/NEJMoa1215637]Search in Google Scholar
[24. Brown JR, O’Brien S, Barrientos JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-223.10.1056/NEJMoa1400376]Search in Google Scholar
[25. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib: an inhibitor of phosphatidylinositol 3-kinase p110 delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390-3397.10.1182/blood-2013-11-535047]Search in Google Scholar
[26. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib: a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123:3406-3413.10.1182/blood-2013-11-538546]Search in Google Scholar
[27. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997-1007.10.1056/NEJMoa1315226]Search in Google Scholar
[28. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011;12:1204-1213.10.1016/S1470-2045(11)70242-X]Open DOISearch in Google Scholar
[29. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008;22:2048-2053.10.1038/leu.2008.214528928318754025]Open DOISearch in Google Scholar
[30. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749-1755.10.1200/JCO.2009.25.3187497910120194866]Open DOISearch in Google Scholar
[31. Montserrat E, Gribben JG. Autografting CLL: the game is over. Blood. 2011;117:6057-6058.10.1182/blood-2011-04-34409321659550]Search in Google Scholar
[32. Sutton L, Chevret S, Tournilhac O, et al. Autologous stem cell transplantation as first-line treatment strategy for chronic lymphocytic leukemia: a multicentre, randomized, controlled trial from the SFGM-TC and GFLLC. Blood. 2011;117:6109-6119.10.1182/blood-2010-11-31707321406717]Search in Google Scholar
[33. Magni M, Di Nicola M, Patti C, et al. Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. Bone Marrow Transplant. 2014;49:485-491.10.1038/bmt.2013.21424442244]Search in Google Scholar
[34. Dreger P, Schetelig J, Andersen N, et al. Managing high risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014;124:3841-3849.]Search in Google Scholar